Clinical Trial Update: Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and tolerability of ALN-TTR01 in transthyretin-mediated amyloidosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-mediated Amyloidosis

Drugs mentioned

• ALN-TTR01

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Transthyretin Mediated Amyloidosis (ATTR) | Phase 1 | Status: COMPLETED